Bioinformation study of immune microenvironment characteristics of disulfidptosis-related subtypes in ovarian cancer and prognostic model construction by Ying Zhou, Yuhong Zhang, Yang Zhou, Yanzheng Gu, Youguo Chen, Juan Wang

Subjects: “…Ovarian cancer…”
Get full text

Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols by Sattar Saima, Ahmad Mobasher, Saeed Hamid, Saleem Zikria, Danish Zeeshan, Akhlaq Muhammad

Subjects: “…ovarian cancer…”
Get full text

Three-dimensional dynamics of mesothelin-targeted CAR.CIK lymphocytes against ovarian cancer peritoneal carcinomatosis by Federica Galvagno, Valeria Leuci, Annamaria Massa, Chiara Donini, Ramona Rotolo, Sonia Capellero, Alessia Proment, Letizia Vitali, Andrea Maria Lombardi, Valentina Tuninetti, Lorenzo D’Ambrosio, Alessandra Merlini, Elisa Vigna, Giorgio Valabrega, Luca Primo, Alberto Puliafito, Dario Sangiolo

Subjects: Get full text

Coffee and its Biologically Active Components: Is There a Connection to Breast, Endometrial, and Ovarian Cancer? - a Review by Anna Maria Witkowska, Iwona Mirończuk-Chodakowska, Katarzyna Maria Terlikowska, Kamila Kulesza, Małgorzata Elżbieta Zujko

Subjects: Get full text

STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer by Changli Qian, Gordon J Freeman, Tao Jiang, Ursula Matulonis, Ziying Lin, Hye-Jung Kim, Anniina Färkkilä, Hua Yu, Xin Cheng, Panagiotis A Konstantinopoulos, Antons Martincuks, Joyce F Liu, Qiwei Wang, Liya Ding, Michael J Kearns, Shaozhen Xie, Inga-Maria Launonen, Thomas M Roberts, Jean J Zhao

“…Background Poly (ADP-ribose) polymerase (PARP) inhibition (PARPi) has demonstrated potent therapeutic efficacy in patients with BRCA-mutant ovarian cancer. However, acquired resistance to PARPi remains a major challenge in the clinic.Methods PARPi-resistant ovarian cancer mouse models were generated by long-term treatment of olaparib in syngeneic Brca1-deficient ovarian tumors. …”
Get full text

PRMT5 promotes ovarian cancer growth through enhancing Warburg effect by methylating ENO1 by Fei Xie, Han Zhang, Kongkai Zhu, Cheng‐Shi Jiang, Xiaoya Zhang, Hongkai Chang, Yaya Qiao, Mingming Sun, Jiyan Wang, Mukuo Wang, Junzhen Tan, Tao Wang, Lianmei Zhao, Yuan Zhang, Jianping Lin, Chunze Zhang, Shuangping Liu, Jianguo Zhao, Cheng Luo, Shuai Zhang, Changliang Shan

Subjects: Get full text

Effects of Self-Assembled Monolayers with Different Chemical Groups on Ovarian Cancer Cell Line Behavior In Vitro by Jie Li, Ting Guan, Chenjun Hao, Lihua Li, Yu Zhang

“…The current study aimed to investigate the effects of different chemical structures present in the ECM on cellular physiology using the ovarian cancer cell line SKOV-3 as a model. Self-assembled monolayers (SAMs) with different chemical modifications, including methyl (-CH3), hydroxyl (-OH), amino (-NH2), carboxyl (-COOH), and mercapto (-SH) groups, were used as microenvironmental models to explore the effects of different structures on SKOV-3 cells. …”
Get full text

Col1A1 as a new decoder of clinical features and immune microenvironment in ovarian cancer by Xiao Xiao, Fangyi Long, Shaolan Yu, Wengjuan Wu, Dayan Nie, Xiaoyan Ren, Wen Li, Xujuan Wang, Ling Yu, Pinghan Wang, Gang Wang

Subjects: Get full text

Pre-injection of exosomes can significantly suppress ovarian cancer growth by activating the immune system in mice by Yuanyuan Wang, Changyi Zhang, Huimin Zeng, Liangliang Wang, Zanhong Wang, Zhiqiang Han

Subjects: Get full text

Immune Response in Ovarian Cancer: How Is the Immune System Involved in Prognosis and Therapy: Potential for Treatment Utilization by Nikos G. Gavalas, Alexandra Karadimou, Meletios A. Dimopoulos, Aristotelis Bamias

“…Ovarian cancer is one of the leading causes of cancer-related death among women. …”
Get full text

GPR137-RAB8A activation promotes ovarian cancer development via the Hedgehog pathway by Chao Tang, Lin Li, Chongying Zhu, Qiang Xu, Zihao An, Shouying Xu, Chao Lin

Subjects: Get full text

CLDN4 as a Novel Diagnostic and Prognostic Biomarker and Its Association with Immune Infiltrates in Ovarian Cancer by Pan Hu, Li Lei, Ying Wang, Xue Tian, Xia Wei, Ni Jiang, Lubin Liu

“…Ovarian cancer (OC) is the seventh most prevalent type of cancer in women and the second most common cause of cancer-related deaths in women worldwide. …”
Get full text

Identification and Clinical Validation of High HSP60 Expression Predicts Poor Prognosis in Patients with Ovarian Cancer by Zheng M, Li S, Deng J, Huang C, Zhang H

Subjects: Get full text

Characterization of tumor prognosis and sensitive chemotherapy drugs based on cuproptosis-related gene signature in ovarian cancer by Wei Tan, Fangfang Dai, Qinyu Ci, Zhimin Deng, Hua Liu, Yanxiang Cheng

Subjects: Get full text

Dietary protein intake and PM2.5 on ovarian cancer survival: A prospective cohort study by He-Li Xu, Yi-Fan Wei, Qi Bao, Ya-Li Wang, Xiao-Ying Li, Dong-Hui Huang, Fang-Hua Liu, Yi-Zi Li, Yue-Yang Zhao, Xin-Xin Zhao, Qian Xiao, Song Gao, Ren-Jie Chen, Ling Ouyang, Xia Meng, Xue Qin, Ting-Ting Gong, Qi-Jun Wu

Subjects: Get full text

Cannabidiol attenuates lipid metabolism and induces CB1 receptor-mediated ER stress associated apoptosis in ovarian cancer cells by Xuanhe Fu, Zhixiong Yu, Fang Fang, Weiping Zhou, Yuxin Bai, Zhongjia Jiang, Biao Yang, Ye Sun, Xing Tian, Guangyan Liu

Subjects: “…Ovarian cancer…”
Get full text

A Rare Case of Metachronous Clear Cell Ovarian Carcinoma and Thyroid Carcinoma: Clinical and Pathological Insights by Ridwan S, Harsono AB, Suardi D, Kurniadi A, Mantilidewi KI, Hidayat YM

Subjects: “…ovarian cancer…”
Get full text

Prehospital care for ovarian cancer in Catalonia: could we do better in primary care? Retrospective cohort study by Mercè Marzo-Castillejo, Josep M Borras, Carmen Vela-Vallespín, Paula Manchon‐Walsh, Luisa Aliste

“…Objective To assess the impact of prehospital factors (diagnostic pathways, first presentation to healthcare services, intervals, participation in primary care) on 1-year and 5-year survival in people with epithelial ovarian cancer (EOC).Design Retrospective quasi-population-based cohort study.Setting Catalan Integrated Public Healthcare System.Participants People with EOC who underwent surgery with a curative intent in public Catalan hospitals between 1 January 2013 and 31 December 2014.Outcome measures Data from primary and secondary care clinical histories and care processes in the 18 months leading up to confirmation (signs and symptoms at presentation, diagnosis pathways, referrals, diagnosis interval) of the EOC diagnosis (stage, histology type, treatment). …”
Get full text

Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis. by Banghyun Lee, Suk-Joon Chang, Byung Su Kwon, Joo-Hyuk Son, Myong Cheol Lim, Yun Hwan Kim, Shin-Wha Lee, Chel Hun Choi, Kyung Jin Eoh, Jung-Yun Lee, Dong Hoon Suh, Yong Beom Kim

“…<h4>Objectives</h4>This meta-analysis was undertaken to systematically evaluate the effects of poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy on the survival of newly diagnosed advanced epithelial ovarian cancer (EOC) patients.<h4>Methods/materials</h4>A systematic literature search revealed 3,227 studies. …”
Get full text

Endometriosis-associated Ovarian Cancer, from Risk Factors to Survival Rate: A Systematic Review and Meta-Analysis by Elham Askary, Saeed Alborzi, Kefayat Chamanara, Alimohammad Keshtvarz Hesam Abadi

“…This meta-analysis aims to assess the prevalence and prognosis of endometriosis-associated ovarian cancer (EAOC) in various types of epithelial ovarian cancer (EOC), and compare risk factors with the non-EAOC group to improve disease management.Method: In this review, PubMed, Science Direct, Scopus, Google Scholar, and Cochrane databases were searched for "endometriosis" and "ovarian cancer risk factor" from 2010 to 2023. …”
Get full text